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COPD, 6-MWD was strongly associated with mortality using 
the median [p  ! 0.001, hazard ratio (HR) = 3.75, 95% confi-
dence interval (CI): 2.24–6.38] or quartiles as cutoff levels. In 
contrast, 6-MWD was only significantly associated with im-
paired survival in RD patients when it was reduced to 204 m 
or less (1st quartile; p = 0.003, HR = 3.31, 95% CI: 1.73–14.10), 
while in OHS 6-MWD had not any prognostic value.  Conclu-
sions: In patients with CHRF and NIV, 6-MWD was predictive 
for long-term survival particularly in COPD. In RD only se-
verely reduced 6-MWD predicted mortality, while in OHS
6-MWD was relatively high and had no prognostic value. 
These results support a disease-specific use of 6-MWD in the 
routine assessment of patients with CHRF. 
 Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 The availability of noninvasive ventilation (NIV) tech-
niques has evoked a large increase in the number of pa-
tients treated with home mechanical ventilation due to 
chronic hypercapnic respiratory failure (CHRF)  [1] . Ow-
ing to improved survival achieved in many diseases, the 
prevalence of these patients is expected to rise progres-
sively  [2] . Most patients treated with home NIV suffer 
from either severe chronic obstructive pulmonary dis-
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 Abstract 
 Background: The 6-min walk distance (6-MWD) is a global 
marker of functional capacity and prognosis in chronic ob-
structive pulmonary disease (COPD), but less explored in 
other chronic respiratory diseases.  Objective: To study the 
role of 6-MWD in chronic hypercapnic respiratory failure 
(CHRF).  Methods: In 424 stable patients with CHRF and non-
invasive ventilation (NIV) comprising COPD (n = 197), restric-
tive diseases (RD; n = 112) and obesity-hypoventilation-syn-
drome (OHS; n = 115), the prognostic value of 6-MWD for 
long-term survival was assessed in relation to that of body 
mass index (BMI), lung function, respiratory muscle function 
and laboratory parameters.  Results: 6-MWD was reduced in 
patients with COPD (median 280 m; quartiles 204/350 m) and 
RD (290 m; 204/362 m) compared to OHS (360 m; 275/440 m; 
p  ! 0.001 each). Overall mortality during 24.9 (13.1/40.5) 
months was 22.9%. In the 424 patients with CHRF, 6-MWD 
independently predicted mortality in addition to BMI, leuko-
cytes and forced expiratory volume in 1 s (p  ! 0.05 each). In 
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ease (COPD), restrictive disorders (RD) or obesity-hy-
poventilation syndrome (OHS)  [1–5] . Until now, interna-
tional guidelines for the specific assessment of patients 
with CHRF undergoing NIV have not been firmly estab-
lished and only few studies focused on clinical measures 
that could be important for monitoring or estimation of 
survival  [3, 6] .
 The 6-min walk distance (6-MWD) is well established 
as a global marker of functional capacity in the cardiore-
spiratory domain, having the advantage of integrating di-
verse physiological components  [7, 8] . Most of the evi-
dence favoring 6-MWD in the evaluation of treatment 
effects  [9–12] and prediction of survival has been ob-
tained in COPD  [8, 13, 14] , consistent with the fact that 
COPD exhibits multiple systemic manifestations beyond 
the respiratory impairment itself  [14–18] , e.g. reductions 
in body mass index (BMI) and fat-free mass  [4, 18] , which 
affect 6-MWD  [19] .
 Low BMI and nutritional depletion are also not un-
common in patients with RD and CHRF  [4] and predic-
tive for survival  [3, 6] . Moreover, chronic or intermittent 
hypoxia could evoke functional changes in skeletal or re-
spiratory muscles similar to COPD  [20–23] and, together 
with a reduction in lung volume, affect exercise capacity. 
Indeed, the 6-MWD has already been used as outcome 
parameter in determining the efficacy of NIV in CHRF 
and RD  [9, 24–27] . Despite that, the clinical significance 
(especially the prognostic value) of 6-MWD in patients 
with CHRF without obstruction is not well explored  [28] . 
Owing to differences in the pathophysiology of diseases 
leading to CHRF, a separate evaluation of patients with 
COPD, OHS and RD might provide further insights.
 Based on this background, we analyzed the associa-
tion between 6-MWD and long-term survival in the pres-
ence of CHRF and NIV in patients with RD and OHS 
compared with COPD. To facilitate the comparison with 
previous data, we also evaluated established risk factors, 
e.g. lung function, BMI and laboratory parameters.
 Patients and Methods 
 Study Population 
 Consecutive patients treated with NIV due to CHRF, who 
were regularly admitted for follow-up to the Center of Pneumol-
ogy, Donaustauf Hospital, University of Regensburg, between 
March 2000 and December 2005, were selected retrospectively 
from a survey data base. Patients were in a stable clinical condi-
tion of either COPD, OHS or RD comprising chest wall diseases 
(CWD), non-progressive neuromuscular disorders (NMD) or in-
terstitial lung diseases (ILD).
 The diagnosis of COPD was based on clinical history, symp-
toms and airway obstruction, i.e. forced expiratory volume in 1 s 
(FEV 1 ) to vital capacity   ! 70% predicted after bronchodilator in-
halation  [29] . OHS was defined by a BMI  1 30, daytime arterial 
carbon dioxide tension  6 45 mm Hg prior NIV therapy and clin-
ical symptoms of CHRF in the absence of other known causes of 
hypoventilation  [30] . Patients with clinical signs of airway infec-
tion, current exacerbation, unstable cardiac arrhythmia or pa-
tients with invasive ventilation were excluded. Additionally, dura-
tion of nocturnal home NIV of  6 3 months was required. The 
study was approved by the local Ethics Committee.
 Assessments 
 On the day of admission, blood gases (Rapidlab; Bayer; East 
Walpole, Mass., USA) were analyzed at rest from the hyperemic 
earlobe. Samples were taken in the daytime during spontaneous 
breathing of room air, if possible, or otherwise during the pa-
tients’ usual oxygen flow. Spirometry and body plethysmography 
(MasterScreen, Viasys, Würzburg, Germany) were performed 
following guidelines of the American Thoracic Society  [31] , using 
reference values of the European Respiratory Society  [32] . For 
measurement of inspiratory mouth occlusion pressure at 100 ms, 
plateau values from five qualitatively acceptable attempts were 
taken. Maximal inspiratory pressure (PI max ) was measured from 
residual volume at maximal inspiratory effort  [33] , and the best 
value of at least three reproducible attempts was documented  [34] . 
Additionally an electrocardiogram was recorded.
 After a phase of recovery, 6-MWD was determined based on 
the guidelines of the American Thoracic Society  [8] while patients 
had their usual oxygen flow. The test was performed on a 30-me-
ter corridor by nurses with specific experience, and its result was 
recorded in absolute values and in percent of predicted (%pred) 
 [35] . Hemoglobin and leukocyte levels were measured using con-
ventional procedures (Micros 60-CT, ABX, Montpellier, France). 
Additionally, BMI calculated as weight/height 2 and comorbidi-
ties were documented.
 Follow-Up 
 All patients were routinely readmitted to the hospital every 6 
months for reevaluation of clinical state and treatment efficacy of 
NIV. During these visits, adherence to NIV was assessed via the 
time counter of the ventilator, and ventilation parameters were 
adjusted according to nocturnal capillary blood gases and oxygen 
saturation. For survival analysis, patients were followed until 
death or until the end of the study period in January 1st, 2006, but 
at least 3 months after discharge. Information on cardiopulmo-
nary or all-cause mortality was obtained from the patients’ rela-
tives and/or family doctors.
 Statistical Analysis 
 For data description, continuous variables are shown as me-
dian values and quartiles. The presence of normal distribution 
was assessed by the Shapiro-Wilk test. Baseline characteristics of 
groups were compared using the Mann-Whitney U test for quan-
titative variables or Fisher’s exact test for binary variables. Sur-
vival was calculated by Kaplan-Meier analysis, starting the day of 
assessment of 6-MWD to the closing date (January 1st, 2006). 
Cutoff values were derived from rounded median values, or from 
the 25th or 75th population percentiles. The predictive value of 
each single variable for all-cause mortality was analyzed by uni-
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variate regression using the log-rank test. Variables significant in 
univariate analyses were entered into a stepwise multivariate Cox 
regression analysis to identify independent predictors, using an 
entry level of p  ! 0.05 and a removal level of 0.10. For all tests, p 
values  ! 0.05 were considered statistically significant. Data were 
analyzed using a statistical software package (version 12.0; SPSS, 
Chicago, Ill., USA).
 Results 
 Study Population 
 The study population comprised 424 patients (262 
males and 162 females) with CHRF due to either severe 
COPD (n = 197; stage IV according to the Global Initia-
tive for Chronic Obstructive Lung Disease)  [36] , OHS
(n = 115) or RD (n = 112). In the group with RD, 68.8%
(n = 77) had CWD, 17.9% (n = 20) NMD and 13.4%
(n = 15) ILD.
 Nocturnal NIV had been initiated 5.6 (median; quar-
tiles: 3.6; 24.5) months prior to enrolment in patients with 
RD/OHS and 7.0 (3.7; 14.4) months in patients with 
COPD; these values did not significantly differ between 
groups. Patients were ventilated either in volume- or 
pressure-cycled assist-controlled mode with an expira-
tory airway pressure of 4 (3; 5) cm H 2 O, an inspiratory 
airway pressure of 22 (18; 24) cm H 2 O and a respiratory 
frequency of 18 (16; 22) per minute. The daily duration of 
ventilator use was 6.8 (4.8; 8.3) h/day. Ventilation param-
eters did not significantly differ between groups. 74.0% 
of the patients with RD/OHS and 96.5% of the patients 
with COPD were on long-term oxygen therapy (p  ! 
0.001).
 6-MWD in absolute values and %pred, as well as age, 
BMI, lung function, mouth occlusion pressures, arterial 
carbon dioxide tension and base excess of patients with 
OHS differed significantly compared to those with COPD 
and RD ( table 1 ). However, no significant differences in 
Table 1. Baseline characteristics of the patients with RD, COPD or OHS
Characteristics COPD (n = 197) RD (n = 112) OHS (n = 115)
Sex, females/males 58/139 60/52a 44/71b
Age, years 66.7 (59.7; 72.6) 66.9 (58.8; 74.4) 58.1 (50.3; 67.5)b, c
BMI, kg/m2 28.6 (23.4; 32.8) 28.3 (23.9; 31.8) 43.3 (36.8; 47.6)b, c
6-MWD, m 280.0 (204.0; 350.0) 290.0 (204.0; 362.0) 360.0 (275.0; 440.0)b, c
6-MWD, %pred 58.6 (40.5; 70.7) 61.3 (44.7; 78.6) 76.6 (61.6; 90.4)b, c
Hemoglobin, g/dl 13.6 (12.4; 14.8) 13.4 (12.4; 14.3) 13.5 (12.5; 15.3)
Leukocytes, 103/l 8.5 (7.0; 10.5) 7.2 (6.0; 8.6)a 8.3 (6.7; 9.8)b
FEV1, liters 0.85 (0.70; 1.17) 0.97 (0.76; 1.23) 2.0 (1.6; 2.5)b, c
VC, liters 2.0 (1.6; 2.4) 1.4 (0.98; 1.7)a 2.7 (2.2; 3.6)b, c
sRaw, kPa ! s 3.8 (2.7; 6.3) 0.98 (0.7; 1.5)a 1.3 (0.9; 1.7)b, c
RV/TLC, % 69.8 (63.2; 76.9) 58.1 (53.5; 63.6)a 46.0 (42.0; 54.8)b, c
P0.1, kPa 0.50 (0.39; 0.62) 0.39 (0.27; 0.50)a 0.36 (0.24; 0.45)c
PImax, kPa 4.2 (3.1; 5.8) 3.7 (2.5; 5.0)a 5.3 (4.0; 8.0)b, c
pH 7.42 (7.40; 7.44) 7.42 (7.40; 7.44) 7.43 (7.41; 7.45)c
PaO2, mm Hg 64.0 (55.0; 71.0) 65.0 (59.0; 72.0)a 64.0 (58.5; 70.5)c
PaCO2, mm Hg 44.0 (40.0; 47.0) 44.0 (40.0; 47.8)a 40.0 (38.0; 43.0)b, c
BE, mmol/l 4.3 (2.1; 7.0) 3.7 (1.6; 5.4) 2.5 (0.5; 4.3)b, c
pH1 7.43 (7.40; 7.45) 7.42 (7.40; 7.44) 7.43 (7.41; 7.45)
PaO2, mm Hg1 56.0 (51.0; 53.0) 62.0 (57.0; 68.0)a 62.0 (57.0; 68.8)
PaCO2, mm Hg1 44.0 (40.0; 47.0) 44.0 (40.0; 47.0) 40.0 (38; 43.0)b, c
BE, mmol/l1 4.1 (2.2; 6.0) 4.0 (1.7; 5.5) 2.3 (0.7; 4.1)b, c
Data are shown as median values and quartiles (in parentheses), except for sex. Characteristics of the groups 
were compared using the non-parametric Mann-Whitney U test. a p < 0.05 vs. COPD, b p < 0.05 vs. RD, and
c p < 0.05 vs. COPD. VC = Vital capacity; sRaw = specific airway resistance; RV = residual volume; TLC = total 
lung capacity; P0.1 = mouth occlusion pressure at 100 ms; PaO2 = arterial oxygen tension; PaCO2 = arterial
carbon dioxide tension; BE = base excess. Blood gas values of all patients were obtained either with oxygen
(median 2.0, quartiles: 1.0, 2.0 l/min) or without.
1 Values were obtained only without oxygen (191 RD patients and 118 with COPD). 
 Six-Minute Walk Test in Chronic 
Respiratory Failure 
Respiration 2008;75:418–426 421
6-MWD (absolute values and %pred) between patients 
with COPD and RD were observed, while sex, leukocyte 
levels, mouth occlusion pressures and lung function were 
different between these groups ( table 1 ). When compar-
ing single diagnoses within RD, only 6-MWD of patients 
with ILD (median 195 m; quartiles 100, 295 m, or 42.0; 
20.7, 70.4%pred) was shorter (p  ! 0.05) compared to pa-
tients with CWD (300 m; 231, 360 m, or 64.2; 50.8, 
79.1%pred) or NMD (290 m; 240, 408 m, or 64.2; 48.5, 
87.1%pred).
 Predictors of Long-Term Survival in the Total 
Population 
 Overall (n = 424), the mean observation time between 
the end of the study period or until patients died was 24.9 
(13.1; 40.5) months. Within this period, 59 patients with 
COPD and 38 patients with RD/OHS died, correspond-
ing to an overall mortality of 22.9%. Deaths resulted pre-
dominantly from respiratory causes (n = 75; 77.3%), in-
cluding respiratory or right heart failure, pulmonary em-
bolism or pneumothorax. The other patients died from 
non-respiratory (n = 15; 15.5%) or unknown causes (n = 
7; 7.2%).
 In univariate analyses of the total population, using 
median values as cutoff, 6-MWD (absolute and %pred;
p  ! 0.001 each;  table 2 ;  fig. 1 ), age, BMI, leukocytes,
specific airway resistance, residual volume to total lung 
capacity, FEV 1 , vital capacity and mouth occlusion pres-
sure at 100 ms ( table 3 ) predicted long-term survival. 
Similar associations were found using the %pred values. 
There were no significant associations of survival with 
hemoglobin (p = 0.119), pH (p = 0.948), arterial oxygen
(p = 0.756) and carbon dioxide tension (p = 0.558), base 
excess (p = 0.203) and PI max (absolute and %pred; p = 
0.071 and 0.137). In a stepwise multivariate Cox regres-
sion analysis, only 6-MWD, BMI, leukocyte number and 
FEV 1 remained as independent predictors of mortality
(p  ! 0.05 each;  table 3 ).
 Prognostic Value of 6-MWD in Different Diseases 
 6-MWD was a strong predictor of long-term survival 
in COPD (n = 197) using the respective median values 
(280 m or 58.6%pred) as cutoff [p  ! 0.001, hazard ratio 
(HR) 3.75, 95% confidence interval (CI) 2.24–6.38; or p  ! 
0.001, HR 3.48, 95% CI 2.06–5.85]. Using quartiles of 6-
MWD, increasing 6-MWD was associated with stepwise 
improved survival (comparison between quartiles: p  ! 
0.001;  fig. 2 ).
 In contrast, 6-MWD was not predictive for survival in 
patients with RD using the median values (290 m or 
61.3%pred) as cutoff. However, using quartiles of 6-MWD 
demonstrated that 6-MWD was significantly associated 
with impaired survival in RD patients when it was re-
duced to 204 m or less (1st quartile; p = 0.003, HR 3.31, 
95% CI: 1.73–14.1) compared with subjects with a 6-
MWD of more than 204 m (p = 0.003,  fig. 3 ). The 2nd, 
3rd and 4th quartiles of 6-MWD did not significantly 
differ regarding survival. In patients with OHS, 6-MWD 
did not have any prognostic value using either the me-
dian value of this population (360 m) or the quartiles 
( fig. 4 ) as cutoff values.
Table 2. Significant prognostic factors according to univariate survival analyses in the total group of patients 
(n = 424)
Variable Median (quartiles) p value HR 95% CI of HR
6-MWD, m 303.0 (232.3; 373.0) <0.0001 2.567 1.701–3.804
6-MWD, %pred 64.8 (47.6; 80.0) <0.0001 2.561 1.682–3.755
Age, years 65.2 (57.1; 71.6) 0.0204 0.622 0.418–0.928
BMI, kg/m2 30.9 (25.3; 37.8) <0.0001 2.518 1.636–3.643
Leukocytes, 103/l 8.0 (6.7; 10.0) 0.0081 0.560 0.360–0.859
FEV1, liters 1.1 (0.8; 1.6) <0.0001 2.440 1.553–3.449
VC, liters 2.0 (1.5; 2.6) 0.0323 1.554 1.038–2.304
sRaw, kPa ! s 2.0 (1.1; 3.7) 0.0391 0.651 0.440–0.979
RV/TLC, % 60.7 (52.3; 70.4) 0.0006 0.480 0.331–0.739
P0.1, kPa 0.43 (0.31; 0.54) 0.0252 0.612 0.404–0.942
p values were according to univariate survival analysis (log-rank test) using the respective median value for 
survival predictors. For abbreviations, please see table 1 and the text.
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 Discussion 
 The present study aimed to evaluate the prognostic val-
ue of 6-MWD in patients with CHRF treated with NIV. 
Within the total population, 6-MWD was an independent 
predictor of mortality in addition to known risk factors 
such as BMI and FEV 1 or leukocyte count. This result was 
mainly attributable to the patients with COPD in whom 
6-MWD was highly predictive for long-term survival 
throughout the whole range of values. In contrast, in pa-
tients with RD and CHRF, only a markedly decreased 6-
MWD predicted increased mortality, while any associa-
tion with OHS was lacking. Thus the prognostic role of 
6-MWD depended on the underlying disease and could 
not be extrapolated from the results obtained in COPD.
 Patients with CHRF are commonly considered to be at 
high risk for death and hospitalization  [3, 37] and NIV is 
often used in the various underlying disorders. As re-
flected in our population, many patients are character-
ized by a restrictive ventilatory pattern resulting predom-
inantly from chest wall deformations, post-tuberculosis 
syndrome or neuromuscular disorders  [38] . More recent-
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 Fig. 1. Prognostic value of either absolute ( a ) or %pred ( b ) values of 6-MWD in CHRF patients (n = 424) using 
the respective median values as cutoff (303 m; p  ! 0.001, and 64.8%pred; p  ! 0.001). 
Table 3. Prognostic value of baseline parameters in the total group of patients (n = 424) according to a stepwise 
Cox multivariate regression analysis
Parameter Cutoff B SE Exp (B) 95% CI of Exp(B) p value
6-MWD, m 303.0 –0.609 0.246 0.544 0.336–0.880 0.013
BMI, kg/m2 30.9 –0.731 0.263 0.481 0.287–0.807 0.005
Leukocytes, 103/l 8.0 0.572 0.229 1.773 1.131–2.773 0.013
FEV1, liters 1.1 –0.603 0.282 0.547 0.315–0.951 0.032
B = Estimate of regression coefficient; SE = standard error of estimate.
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ly, OHS also became a major indication  [1, 5] . Recent 
findings have indicated that long-term NIV has an im-
pact on survival in many of these diseases  [39–41] , con-
sequently knowledge of outcome parameters is essential 
to best utilize the potential of NIV therapy.
 In the present study, BMI, leukocyte counts and FEV 1 
were found to be major predictors for long-term survival 
in CHRF patients. Evidence has already been provided 
that nutritional depletion and systemic inflammation are 
common in patients with respiratory failure and, there-
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 Fig. 2. Prognostic value of 6-MWD in patients with COPD (n = 
197) comparing the quartiles of 6-MWD (0–204, quartile 1; 205–
280, quartile 2; 281–350, quartile 3, and  1 350 m, quartile 4; log-
rank test; p  ! 0.001). Significant differences in long-term surviv-
al were present between quartile 1 and 2 (p = 0.015), 3 (p  ! 0.001) 
and 4 (p  ! 0.001), quartile 2 and 4 (p  ! 0.001), quartile 3 and 4
(p = 0.047), but not between quartile 2 and 3 (p = 0.207). 
 Fig. 3. Prognostic value of 6-MWD in patients with RD (n = 112) 
comparing the quartiles of 6-MWD (0–204, quartile 1; 205–290, 
quartile 2; 291–362, quartile 3, and  1 362 m, quartile 4; log-rank 
test; p = 0.003). Significant differences in long-term survival were 
obtained when comparing quartile 1 to each of the other quartiles 
(p  ! 0.05 each). Survival was not significantly different between 
the 2nd, 3rd and 4th quartile. 
 Fig. 4. Prognostic value of 6-MWD in patients with OHS (n = 115) 
comparing the quartiles of 6-MWD (0–275, quartile 1; 276–360, 
quartile 2; 361–440, quartile 3, and  1 440 m, quartile 4; log-rank; 
p = 0.783). Survival was not significantly different between each 
of the quartiles. 
 2 
4
3
 Budweiser et al. 
 
Respiration 2008;75:418–426424
fore, represent important risk factors beyond the respira-
tory impairment  [3, 6] . In previous analyses partially in-
cluding the same patients, we also found associations be-
tween survival, inflammatory markers and BMI  [41,  42] . 
Based on the concept that 6-MWD is an integrative mea-
sure comprising different physiologic components, it 
seems plausible that 6-MWD was an independent predic-
tor of long-term mortality within the total group of pa-
tients with CHRF and NIV.
 To further elucidate this novel finding, we separately 
analyzed patients with either COPD, RD or OHS, reveal-
ing that the associations of 6-MWD with long-term sur-
vival observed in the overall population were to a great 
extent due to the COPD subgroup. In line with this, 6-
MWD in COPD is known to be valuable for clinical as-
sessment, monitoring and prediction of survival  [10–14, 
43–45] . Recent data even suggest that 6-MWD can indi-
cate clinical changes not detectable in the sequential eval-
uation of pulmonary impairments alone  [44] . Our find-
ings additionally elucidated 6-MWD as a sensitive mea-
sure with regard to long-term survival in patients with 
COPD and CHRF. As shown by the analysis of quartiles, 
6-MWD was highly predictive of mortality throughout 
its rather small range independent of lung function im-
pairment.
 Associations of 6-MWD with mortality have also been 
detected in primary pulmonary hypertension  [46] , chron-
ic heart diseases  [47] or, more recently, idiopathic pulmo-
nary fibrosis  [48] , but knowledge on the role of 6-MWD 
in other, particularly restrictive, chronic respiratory dis-
orders is rather limited. Our data indicated that the me-
dian 6-MWD in RD (290 m) was as low as in COPD
(280 m) and that the two groups did not significantly dif-
fer in BMI, although BMI might obscure a loss of fat-free 
mass  [4] . Nevertheless, compared to COPD, the prognos-
tic value of 6-MWD was lower in RD and present only 
when using the 1st quartile as cutoff. In OHS, knowledge 
on the significance of 6-MWD is scarce, and we could not 
reveal any prognostic value. These patients showed a rela-
tively high 6-MWD, which seemed plausible in view of the 
low age but high BMI, lung volumes and PI max , all of which 
predict high exercise capacity in chronic respiratory dis-
eases  [7, 49] . Of course, our data do not implicate that 6-
MWD has no value in the assessment of treatment effects 
in OHS or RD, as particularly these patients showed im-
proved walking distances after initiation of NIV  [9] .
 Different factors might explain the weaker impact of 
6-MWD on survival in RD or OHS compared to COPD. 
As recent data suggest, patients with RD or OHS have a 
favorable prognosis while using NIV  [39–41] , which 
might have rendered it more difficult to reveal an asso-
ciation with 6-MWD. This argument does, however, not 
invalidate our conclusion, as a weaker statistical associa-
tion also implies a lower predictive power in practice. 
Secondly, systemic inflammation is thought to play a role 
in nutritional depletion, skeletal muscle dysfunction and 
mortality  [16] . Correspondingly, leukocyte numbers were 
highest in COPD. Thirdly, most of the patients with RD 
suffered from CWD with large skeletal deformities which 
may affect 6-MWD without being reflected in survival.
 To our knowledge, there is one comprehensive study 
of similar size (n = 446) considering the relationship be-
tween 6-MWD and long-term survival in patients with 
chronic respiratory diseases receiving long-term oxygen 
therapy and/or home mechanical ventilation  [6] . 6-MWD 
turned out as a prognostic factor in univariate analyses 
but was no independent predictor, possibly due to the 
lower proportion of COPD (42.8 vs. 53.5% in the present 
study). The study did not report data on restrictive and 
obstructive disorders separately. A previous study com-
prising 149 patients with chronic respiratory diseases af-
ter pulmonary rehabilitation (89% COPD, 8% asthma, 
2% CWD and 1 patient with ILD) demonstrated 6-MWD 
to be strongly related to survival, again supporting its role 
particularly in COPD  [45] . Our data extend these find-
ings by demonstrating that in CHRF 6-MWD has prog-
nostic value mainly in COPD or in severe RD.
 While our study had the advantage of comprising large 
patient cohorts with RD or COPD, some aspects require 
attention in interpretation. Limitations of our study were 
the retrospective design and the fact that all patients were 
under NIV treatment. We only included patients who 
continuously used NIV documented in regular follow-up 
visits. It is thus not possible to compare our findings with 
that of a control group without NIV. As the great major-
ity of patients with CHRF is treated with NIV, we thus 
assured a rather homogeneous condition with regard to 
the treatment considered most effective in CHRF. The 
data obtained in COPD also served to assess the validity 
of the analysis. Indeed, they turned out to be fully consis-
tent with previously published reports.
 In summary, the present study comprising patients 
with CHRF under NIV treatment demonstrated 6-MWD 
to be an independent predictor of long-term survival. 
This result was mainly attributable to COPD, while in RD 
the prognostic value of 6-MWD was limited to severely 
impaired patients. In OHS, 6-MWD was rather high and 
not predictive of mortality. In conclusion, our data sug-
gest a disease-specific use of 6-MWD to assess and mon-
itor NIV-treated patients with CHRF. 
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